DAILY DOSE AND COSTS ASSOCIATED WITH MAINTENANCE THERAPY OF TOPICAL TESTOSTERONE AGENTS AMONG HYPOGONADAL MEN

Author(s)

Kaltenboeck A¹, Boytsov N², Hayes-Larson E¹, San Roman A¹, Ivanova J¹, Birnbaum H³, Foster S², Vazquez J², Muram D², Swindle R²
¹Analysis Group, Inc., New York, NY, USA, ²Eli Lilly and Company, Indianapolis, IN, USA, ³Analysis Group, Inc., Boston, MA, USA

Presentation Documents

PIH84-kaltenboeck-a-sup-1-sup-strong-u-boytsov-n-u-sup-2-sup-strong-hayes-larson-e-sup-1-sup-san-roman-a-sup-1-sup-ivanova-j-sup-1-sup-birnbaum-h-sup-3-sup-foster-s-sup-2-sup-vazquez-j-sup-2-sup-muram-d-sup-2-sup-swindle-r-sup-2-sup-br-sup- ...

OBJECTIVES: Topical testosterone agents (TTAs) are commonly used to raise low serum levels of testosterone in men. After initiating at a recommended starting dose (RSD), patients may undergo dose titration to achieve an appropriate maintenance dose. The objective of this study was to compare daily maintenance doses and costs of treatment with TTAs from US payer perspective in adult men diagnosed with Hypogonadism (HG). METHODS: Adult men with a HG-associated diagnoses initiated at the RSD with Axiron^® (Lilly USA, LLC; RSD 60mg per day; N=209), AndroGel^®

Conference/Value in Health Info

2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands

Value in Health, Vol. 17, No. 7 (November 2014)

Code

PIH84

Topic

Health Policy & Regulatory, Health Service Delivery & Process of Care

Topic Subcategory

Prescribing Behavior, Reimbursement & Access Policy, Treatment Patterns and Guidelines

Disease

Reproductive and Sexual Health

Presentation